Stay informed on key pharmaceutical news, including tariff updates, FDA shutdown risks, and insights from recent cell and gene therapy reviews. Welcome to Pharmaceutical Executive Daily, your quick ...

Takeda discontinues cell therapy efforts, seeking external partnerships to leverage platform technologies and advance research programs. Focus shifts to near-term investments in small molecules, ...

Gen Li, founder and president of Phesi, discusses how the rise of GLP-1 medications is impacting how various diseases are treated beyond the ones the medications are specifically designed to treat.

Vanda and FDA's agreement includes expedited re-reviews of Tradipitant and Hetlioz applications, with target action dates in late 2025 and early 2026. The collaborative framework involves pausing ...

President Trump is using the threat of 100% tariffs on pharma imports as a negotiation tactic to lower drug prices. Pfizer has secured a three-year tariff exemption by agreeing to reduce drug prices ...

The FDA will maintain essential functions during the shutdown, focusing on public health and safety, including outbreak monitoring and high-risk recalls. New drug, biological, and medical device ...

AI is transforming drug discovery, optimizing RNA molecule design, and enhancing clinical trial strategies, making it essential for companies to integrate AI into workflows. Predictive analytics in AI ...

How cell and gene therapy developers can lessen the chances of receiving FDA complete response letters through the use of proactive chemistry, manufacturing, and controls strategies.

In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s resubmission of its BLA for Awiqli, the FDA’s approval of Kedrion’s Qivigy for primary humoral immunodeficiency, and Eli Lilly’s ...

Halozyme Therapeutics acquires Elektrofi for $750 million, enhancing drug delivery technology with Hypercon's innovative microparticle approach for biologics.

Novartis gains FDA approval for Rhapsido, the first oral BTK inhibitor for Chronic Spontaneous Urticaria, offering new hope for patients.

In today’s Pharmaceutical Executive Daily, we cover AbbVie’s new API manufacturing site in Illinois, AstraZeneca’s plan to harmonize its global stock exchange listings, and reports that President ...